The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Lung cancer highlights at ESMO 2026 : PERSEE and DeLLphi-305
Martin Sebastian, MD, Goethe University Frankfurt, Frankfurt am Main, Germany, discusses recent advances in lung cancer treatment, highlighting the PERSEE trial (GFPC 01-2020; EudraCT 2020-002626-86), which potentially establishes a new standard of care in PD-L1 over-expressing patient populations. Additional trials of note include the DeLLphi-305 trial (NCT06211036) of tarlatamab and durvalumab in first-line extensive-stage small cell lung cancer (ES-SCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have seen the PERSEE trial, the French trial. Which has set a completely new standard. They have shown that in the PD-L1 over-expressing patient population the PFS is much, much longer by chemotherapy plus IO. So that’s going to be the new standard of care which is comes a little bit astonishing for me. And the highlight yesterday was of course the tarlatamab in the first line maintenance small cell lung cancer which is completely yeah wouldn’t completely, wouldn’t have thought about data like this five years ago...
We have seen the PERSEE trial, the French trial. Which has set a completely new standard. They have shown that in the PD-L1 over-expressing patient population the PFS is much, much longer by chemotherapy plus IO. So that’s going to be the new standard of care which is comes a little bit astonishing for me. And the highlight yesterday was of course the tarlatamab in the first line maintenance small cell lung cancer which is completely yeah wouldn’t completely, wouldn’t have thought about data like this five years ago. This is really changing the landscape and we are we are extremely glad that in small cell cancer we are doing we’re doing better in the last year. That’s extremely good.
Read more...
